Track topics on Twitter Track topics that are important to you
DelveInsight's, Velmetia API Insights, 2017 report provides product and API manufacturers details across the globe along with the location. The report gives the clear idea on the country wise DMF filed by worldwide companies related to the Velmetia. The report also highlights the patent details of Velmetia.
The report is built using data and information sourced from proprietary databases, primary and secondary research and inhouse analysis by DelveInsight team of industry experts.
Secondary sources information and data has been collected from various printable and nonprintable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Magazines, Trade associations, Books, Industry Portals, Industry Associations and access to available databases.
Evaluate the marketing status of Velmetia to exploit opportunities for generic Velmetia development opportunities
Design effective counterstrategies to gain competitive advantage by identifying the key patent expiry details with respect to Velmetia
API intelligence over Velmetia and gaining primary intelligence over Active Ingredient manufacturers by country
Make more informed business decisions from insightful and indepth analysis of the Velmetia's performance
type 2 diabetes mellitus
Velmetia Marketed Drugs Overview
Velmetia Market Assessment
Velmetia API Manufacturers/ Active Pharmaceutical Ingredients Manufacturers
Velmetia US DMF
Velmetia US Drug Master Files
Velmetia Active Substance Master File/ EUDMF
Velmetia Generic players
Velmetia Patent Expiration
Velmetia Patent Exclusivity
Velmetia API Manufacturers
Velmetia Global Forecasted Sales Figure
A generic drug (generic drugs, short: generics) is a drug defined as "a drug product that is comparable to brand/reference listed drug product in dosage form, strength, route of administration, quality and performance characteristics, and intended u...
Merck and Co
Merck & Co is the 7th largest pharmaceutical company in the world based on annual sales, which reached $25,236m in 2009. They have developed 14 vaccines and over 40 prescription products in the major therapeutic areas of cardiovascular disease, respi...